Leqvio (Inclisiran) in Hispanic / Latino Patients: Safety Profile Differences

What Is Inclisiran and Why Does Ethnicity Matter?

Inclisiran is the first-in-class small interfering RNA (siRNA) approved to lower LDL cholesterol by silencing hepatic PCSK9 messenger RNA. The FDA granted approval on December 22, 2021, based primarily on the ORION trial program [1]. Unlike monoclonal antibody PCSK9 inhibitors given every two to four weeks, inclisiran requires only two injections per year after the loading phase, which has practical relevance for populations with documented gaps in medication adherence.

Ethnicity matters here for at least three interacting reasons. First, Hispanic and Latino adults in the United States carry a disproportionate burden of atherosclerotic cardiovascular disease (ASCVD) risk factors, including type 2 diabetes, central adiposity, and hypertriglyceridemia [2]. Second, genetic ancestry influences the frequency of pharmacogenomic variants that affect co-prescribed statin tolerability, and most Hispanic / Latino patients on inclisiran are also taking a background statin [3]. Third, representation of Hispanic and Latino participants in the ORION trials was limited, making post-hoc subgroup analyses necessary reading before extrapolating efficacy and safety data to clinical practice.

The ORION Trial Program: Enrollment and Representation

ORION-10 (N=1,561, United States) and ORION-11 (N=1,617, United States and Europe) are the key phase 3 placebo-controlled randomized controlled trials published in the New England Journal of Medicine in 2020 [1]. Both enrolled adults with established ASCVD or ASCVD-risk equivalents on maximally tolerated statin therapy. Hispanic and Latino participants were enrolled primarily through ORION-10 US sites.

Across the pooled ORION-10 and ORION-11 population, the overall LDL-C reduction was 49.9% from baseline at day 510 for inclisiran versus a 1.0% reduction for placebo (P<0.001) [1]. The trials were not powered to detect ethnicity-specific differences, and the published manuscripts do not report a separate Hispanic / Latino subgroup forest plot. Novartis has disclosed aggregate demographic data showing Hispanic / Latino enrollment was under 10% of the total ORION-10 cohort, consistent with enrollment gaps seen across cardiovascular outcomes trials.

Cardiovascular Risk Context in Hispanic / Latino Adults

The CDC reports that Hispanic and Latino adults die from heart disease at rates that, while slightly lower in raw age-adjusted terms than non-Hispanic whites, occur at younger ages and with higher rates of uncontrolled risk factors [2]. The American Heart Association's 2024 Heart Disease and Stroke Statistics noted that Mexican American adults have a 12.5% prevalence of diagnosed diabetes versus 7.5% in non-Hispanic whites [4]. Insulin resistance and central adiposity accelerate the atherogenic dyslipidemia pattern (high triglycerides, low HDL, small dense LDL), which inclisiran directly addresses through LDL-C reduction even if it does not alter triglycerides or HDL.

Safety Profile of Inclisiran: What the Overall Data Show

The overall safety profile of inclisiran from pooled ORION-9, ORION-10, and ORION-11 data (N=3,655 inclisiran-treated patients) shows a favorable tolerability picture at up to 18 months of follow-up [1, 5].

Injection-Site Reactions

Injection-site reactions are the most frequently reported adverse event. In the pooled ORION analysis, these occurred in 2.6% of inclisiran-treated patients versus 0.9% of placebo patients [1]. Reactions were predominantly mild-to-moderate erythema, pain, or transient swelling. No anaphylaxis was reported. The FDA prescribing information characterizes injection-site reactions as the primary safety signal and does not list ethnicity as a modifying factor for this outcome [6].

Hepatic and Renal Safety

Inclisiran is taken up by the liver via GalNAc-mediated asialoglycoprotein receptor binding, which means hepatic delivery is highly targeted. Alanine aminotransferase (ALT) elevations above three times the upper limit of normal occurred in 2.3% of inclisiran patients versus 1.6% of placebo patients in ORION-11 [1]. No cases of drug-induced liver injury meeting Hy's Law criteria were reported. Because Hispanic and Latino individuals have higher rates of non-alcoholic fatty liver disease (NAFLD, now termed MAFLD), baseline liver enzyme monitoring before starting inclisiran is a sensible clinical step, even though the FDA label does not mandate it [7].

Renal safety data from ORION-10 showed no significant difference in eGFR trajectories between inclisiran and placebo over 18 months [1]. The FDA label confirms no dose adjustment is required for mild-to-moderate chronic kidney disease [6].

Musculoskeletal Adverse Events

Unlike statins, inclisiran has no direct mechanism causing myopathy. Myalgia rates in the ORION trials were comparable between the inclisiran and placebo arms (3.8% vs. 4.0%) [1]. This is relevant for Hispanic / Latino patients who carry background statin myopathy risk related to SLCO1B1 pharmacogenomic variants (discussed in the pharmacogenomics section below).

Pharmacogenomics: What Genetic Ancestry Means for Inclisiran Co-therapy

Inclisiran itself is not metabolized by cytochrome P450 enzymes and is not a substrate of P-glycoprotein or major drug transporters in a clinically meaningful way. The FDA label lists no drug-drug interactions [6]. That narrow pharmacogenomic profile is one of the drug's practical advantages.

SLCO1B1 and Statin Co-therapy

The real pharmacogenomic concern in Hispanic / Latino patients is not inclisiran itself but the statin that virtually every patient continues alongside it. The SLCO1B1 gene encodes organic anion transporting polypeptide 1B1 (OATP1B1), which mediates hepatic uptake of most statins. The SLCO1B1 c.521T>C variant (rs4149056) reduces OATP1B1 function and increases systemic statin exposure, raising myopathy risk [3]. PharmGKB classifies this variant as a Level 1A pharmacogenomic association for simvastatin-induced myopathy [3].

Allele frequency data from the 1000 Genomes Project and gnomAD show that the c.521T>C minor allele occurs in approximately 14% of admixed Latin American individuals, compared with approximately 12% in European-ancestry populations and 1 to 2% in African-ancestry populations [3]. The difference is modest but not negligible. A Hispanic / Latino patient on high-dose simvastatin who begins inclisiran therapy is not at risk from inclisiran itself, but the co-prescribing clinician should be aware that statin myopathy could emerge and be misattributed to the new agent.

The Clinical Pharmacogenomics Implementation Consortium (CPIC) guideline recommends against simvastatin 80 mg in any patient with the SLCO1B1 reduced-function genotype and suggests switching to rosuvastatin, pravastatin, or pitavastatin as lower-risk alternatives [3].

CYP2C9 and Rosuvastatin

Rosuvastatin is among the statins most commonly paired with inclisiran in high-intensity regimens. CYP2C9 poor metabolizer status, driven by the CYP2C92 and 3 alleles, increases rosuvastatin plasma exposure by approximately 30 to 40% [8]. CYP2C92 frequency in admixed Latin American populations is approximately 8 to 10%, comparable to European populations [8]. CYP2C93 is rarer (approximately 2 to 3%) but associated with a larger effect on rosuvastatin clearance. Clinicians initiating inclisiran alongside rosuvastatin 40 mg in a Hispanic / Latino patient may consider pharmacogenomic testing if myalgia or transaminase elevation develops, before concluding the new siRNA is responsible.

PCSK9 Gain-of-Function Variants by Ancestry

Certain PCSK9 gain-of-function (GOF) variants associated with familial hypercholesterolemia are more prevalent in specific Latino subpopulations. The p.Arg97Trp and p.Asp374Tyr variants have been documented in Mexican and South American cohorts in case series [9]. Patients carrying these variants have higher baseline LDL-C and may theoretically derive larger absolute LDL-C reductions from inclisiran, though no published prospective data confirm differential inclisiran efficacy by PCSK9 GOF genotype in Hispanic / Latino individuals.

Diabetes, Insulin Resistance, and Metabolic Interactions

Hispanic and Latino adults have the second-highest prevalence of type 2 diabetes among US racial and ethnic groups, at approximately 12.5% [2]. This has specific implications for inclisiran use because statins (the backbone co-therapy) modestly increase diabetes incidence, and the clinical question is whether inclisiran modifies that risk.

Inclisiran and Glycemic Outcomes

ORION-10 and ORION-11 both collected HbA1c data as a safety endpoint. Inclisiran produced no statistically significant change in HbA1c at 18 months in either trial [1]. The pooled ORION analysis confirmed no difference in new-onset diabetes between the inclisiran and placebo arms (2.2% vs. 2.4%) [1]. This is reassuring for the Hispanic / Latino patient population, which already carries elevated diabetes risk from statin co-therapy.

Triglycerides and Atherogenic Dyslipidemia

Inclisiran reduces LDL-C by approximately 50% but produces only modest reductions in triglycerides (approximately 5 to 8% in ORION data) and no meaningful change in HDL-C [1]. The atherogenic dyslipidemia phenotype common in insulin-resistant Hispanic / Latino adults (high triglycerides, low HDL, elevated apoB) will not be fully corrected by inclisiran alone. Clinicians should address residual triglyceride burden with fibrates or icosapentaenoic acid (IPE, as studied in REDUCE-IT [10]) alongside inclisiran when fasting triglycerides exceed 150 mg/dL.

The HealthRX clinical team proposes a tiered metabolic monitoring framework for Hispanic / Latino patients starting inclisiran:

• Baseline visit: fasting lipid panel (LDL-C, triglycerides, HDL, non-HDL), HbA1c, ALT/AST, eGFR, and PCSK9 GOF screening if family history suggests FH.
• Day 90 (second injection visit): repeat LDL-C and ALT. Ask specifically about myalgia to catch statin-related symptoms before the next six-month interval.
• Month 12 and annually: full fasting lipid panel, HbA1c, ALT, and eGFR. If triglycerides remain above 150 mg/dL, consider add-on therapy rather than increasing inclisiran dose (dose escalation is not supported by the label or any published data).

Dosing: Is Any Adjustment Required for Hispanic / Latino Patients?

No ethnicity-specific dose adjustment for inclisiran is required or recommended by the FDA label as of the January 2025 label version [6]. The approved regimen is 284 mg subcutaneous injection on day 1, day 90, then once every six months.

Renal Considerations

The FDA label states that pharmacokinetic modeling showed no clinically meaningful change in inclisiran systemic exposure across eGFR categories from 15 to 90 mL/min/1.73m² [6]. No dose adjustment is required for patients with mild-to-moderate CKD. Given the elevated CKD prevalence in Hispanic / Latino adults with diabetes, this is clinically relevant reassurance.

Hepatic Considerations

Mild-to-moderate hepatic impairment (Child-Pugh A or B) does not alter inclisiran pharmacokinetics in a manner requiring dose adjustment [6]. The drug has not been studied in severe hepatic impairment (Child-Pugh C). Given the higher NAFLD / MAFLD burden in Hispanic / Latino adults, baseline transaminase assessment is recommended before the first injection, though the FDA label does not set a formal contraindication threshold for elevated ALT.

Body Weight and BMI

Inclisiran pharmacokinetic data showed no significant effect of body weight on LDL-C lowering in the ORION trials across a BMI range of 18 to 50 kg/m² [1]. No weight-based dose adjustment is recommended. Hispanic / Latino adults have a higher mean BMI and higher rates of central adiposity compared with non-Hispanic white adults [2], but current evidence does not support a different dosing strategy based on weight alone.

Real-World Safety Data and Post-Marketing Surveillance

As of January 2025, inclisiran has been commercially available in the United States for approximately three years. The FDA Adverse Event Reporting System (FAERS) database contains post-marketing reports primarily of injection-site reactions and musculoskeletal complaints, consistent with the clinical trial safety profile [6]. No ethnicity-stratified post-marketing safety signals have been published or highlighted in FDA safety communications for inclisiran.

The ORION-4 cardiovascular outcomes trial (N=15,000, ongoing, estimated completion 2026) includes broader real-world enrollment and may generate more granular ethnicity-stratified data [11]. Until those results are published, clinicians must rely on the pooled ORION-10 and ORION-11 safety data and pharmacogenomic reasoning to inform practice in Hispanic / Latino patients.

Adherence and Access Considerations

The twice-yearly injection schedule reduces the adherence burden compared with daily oral lipid-lowering agents or monthly injectable PCSK9 inhibitors. Adherence gaps in Hispanic / Latino populations have been documented for chronic disease medications and relate to factors including cost, insurance coverage, and healthcare access rather than pharmacological differences [4]. The Novartis patient support program (Leqvio Together) provides cost assistance and injection training, which may specifically benefit patients navigating language barriers or high-deductible insurance plans.

The American Heart Association's 2023 statement on health equity in cardiovascular care emphasizes that interventions reducing injection frequency and removing adherence barriers show particular promise in populations with historically lower medication persistence [4].

Clinical Guidance: Applying ORION Evidence to Hispanic / Latino Patients

The 2022 ACC/AHA cholesterol guideline states that PCSK9-targeted therapies, including inclisiran, are appropriate for adults with LDL-C at or above 70 mg/dL on maximally tolerated statin therapy who have established ASCVD or an ASCVD risk equivalent [12]. The guideline does not stratify this recommendation by ethnicity, and no society guideline currently recommends a different inclisiran dose or monitoring interval for Hispanic / Latino patients.

When to Choose Inclisiran Over Monoclonal PCSK9 Inhibitors

In a Hispanic / Latino patient with established ASCVD and adherence challenges (documented by pharmacy refill gaps), the twice-yearly injection schedule of inclisiran may offer a practical advantage over evolocumab (monthly or bimonthly) or alirocumab (bimonthly). Both monoclonal antibodies and inclisiran produce similar LDL-C reductions (approximately 50 to 60% from baseline) when added to maximally tolerated statin therapy [1, 13].

A clinician choosing between these agents should weigh the patient's LDL-C target, prior authorization requirements, and injection frequency preference rather than ethnicity-specific pharmacological differences.

Familial Hypercholesterolemia Screening

The Familial Hypercholesterolemia Foundation and ACC recommend cascade screening for first-degree relatives when FH is suspected [12]. Hispanic and Latino families with a proband carrying a PCSK9 GOF variant or LDL receptor (LDLR) pathogenic variant should undergo genetic counseling. Inclisiran is approved for heterozygous FH in adults and produces LDL-C reductions of approximately 44% in the ORION-9 FH-specific trial (N=482) [5].